menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing the High Cost of Prescription Drugs in the U.S.

close
Reducing the High Cost of Prescription Drugs in the U.S.
Restart
Resume
Choose a format
Media formats available:
Details
Related
Comments
  • In Partnership with

  • Overview

    [Read the Article]

    The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers.  A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.

    Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.

    The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.

    [Watch more videos of The JAMA Report]

Facebook Comments

Recommended
Details
Related
Comments
  • In Partnership with

  • Overview

    [Read the Article]

    The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers.  A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.

    Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.

    The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.

    [Watch more videos of The JAMA Report]

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/2/20